Please check your internet connection and try again.
# Sompraz HP
## Overview
Sompraz HP is a co-packaged "Helicobacter pylori kit" containing a combination of **Esomeprazole** (a proton pump inhibitor), **Amoxicillin** (a penicillin antibiotic), and **Clarithromycin** (a macrolide antibiotic). It is designed for the eradication of *H. pylori* and the treatment of associated peptic ulcer disease.
## Primary Indications
Treatment of *Helicobacter pylori* infection in patients with duodenal ulcer disease or chronic gastritis to reduce the risk of duodenal ulcer recurrence.
## Adult Dosing
Standard regimen consists of the following taken twice daily (morning and evening) for 7 to 14 days:
* **Esomeprazole:** 40 mg twice daily.
* **Amoxicillin:** 1000 mg twice daily.
* **Clarithromycin:** 500 mg twice daily.
Always follow the manufacturer's specific pack instructions, as some kits vary in total duration (typically 14 days is preferred for optimal eradication rates).
## Pediatric Dosing
Safety and efficacy have not been established in the pediatric population. Use is generally not recommended in children.
## Dose Adjustments
* **Renal Impairment:** No specific adjustment for esomeprazole. Adjustments for amoxicillin and clarithromycin are required if CrCl < 30 mL/min; consult a pharmacist or renal dosing guidelines specifically for these components.
* **Hepatic Impairment:** Use caution with esomeprazole (max dose 20 mg/day in severe impairment). No specific adjustments for amoxicillin, but use clarithromycin with caution.
## Contraindications
* Hypersensitivity to esomeprazole, amoxicillin, clarithromycin, or any other macrolide or beta-lactam antibiotic.
* Concomitant use with cisapride, pimozide, astemizole, or terfenadine (due to risk of QT prolongation/arrhythmias with clarithromycin).
* History of cholestatic jaundice or hepatic dysfunction with prior clarithromycin use.
## Adverse Effects
* **Common:** Diarrhea, nausea, vomiting, abdominal pain, dysgeusia (metallic taste), and headache.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), severe hypersensitivity reactions (anaphylaxis/SJS/TEN), QT prolongation, and acute interstitial nephritis.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Substrates:** Clarithromycin is a potent CYP3A4 inhibitor; significant interactions exist with statins (increased rhabdomyolysis risk), colchicine, and oral anticoagulants (e.g., warfarin).
* **pH-Dependent Drugs:** Esomeprazole may decrease the absorption of drugs requiring acidic environments (e.g., atazanavir, ketoconazole).
* **Methotrexate:** PPIs may increase serum levels of methotrexate.
## Monitoring
* Monitor for signs of *C. difficile* infection (persistent, severe, or bloody diarrhea).
* Assess for allergic reactions or cutaneous eruptions.
* Monitor INR if taking warfarin during the course.
* Verify *H. pylori* eradication via urea breath test or stool antigen test at least 4 weeks after therapy completion.
## Clinical Pearls
* Adherence is critical; failure to complete the full 14-day course significantly increases the risk of antibiotic resistance.
* Take consistently at the same times each day.
* Consider clarithromycin resistance patterns in your local area; if local resistance is >15%, bismuth-based quadruple therapy is often preferred over triple therapy (PPI + Clarithromycin + Amoxicillin).
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical dosing and indications may vary based on local guidelines, regional resistance profiles, and specific patient factors. Always verify the most current prescribing information and confirm doses against the specific product labeling or institutional clinical protocols before prescribing or administering.
